Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study Of AVB-S6-500 In Combination With Cabozantinib, AVB-S6-500 In Combination With Cabozantinib and Nivolumab, and AVB-S6-500 Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT04300140 is registered in ClinicalTrials.gov with Aravive, Inc. as lead sponsor.

NCT NCT04300140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04300140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study Of AVB-S6-500 In Combination With Cabozantinib, AVB-S6-500 In Combination With Cabozantinib and Nivolumab, and AVB-S6-500 Monotherapy in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Lead sponsor
Aravive, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 26, 2021
Completion date
August 14, 2023
Enrollment
72 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma